Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Scribd Logo
Upload

Welcome to Scribd!

  • 48 views

    Natco Pipeline

    Uploaded by

    nikesh.nikzag
    This document summarizes key details about generic drug approvals and patent expirations for several brand name drugs. It includes the brand and generic drug names, innovator company, potential generic partners, market size, and notes on patent challenges and expirations. Key drugs discussed include Pomalyst, KYPROLIS, Eliquis, Ozempic, Lynparza, and others. Potential generic filings and partners are listed, along with details on patent challenges and expected expiry dates ranging from 2025 to 2036.

    Copyright:

    © All Rights Reserved
    Download as XLSX, PDF, TXT or read online from Scribd

    Natco Pipeline

    Uploaded by

    nikesh.nikzag
    48 views5 pages
    This document summarizes key details about generic drug approvals and patent expirations for several brand name drugs. It includes the brand and generic drug names, innovator company, potential generic partners, market size, and notes on patent challenges and expirations. Key drugs discussed include Pomalyst, KYPROLIS, Eliquis, Ozempic, Lynparza, and others. Potential generic filings and partners are listed, along with details on patent challenges and expected expiry dates ranging from 2025 to 2036.

    Copyright

    © © All Rights Reserved

    Available Formats

    XLSX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    This document summarizes key details about generic drug approvals and patent expirations for several brand name drugs. It includes the brand and generic drug names, innovator company, potential generic partners, market size, and notes on patent challenges and expirations. Key drugs discussed include Pomalyst, KYPROLIS, Eliquis, Ozempic, Lynparza, and others. Potential generic filings and partners are listed, along with details on patent challenges and expected expiry dates ranging from 2025 to 2036.

    Copyright:

    © All Rights Reserved
    Download as XLSX, PDF, TXT or read online from Scribd
    Download as xlsx, pdf, or txt
    48 views5 pages

    Natco Pipeline

    Uploaded by

    nikesh.nikzag
    This document summarizes key details about generic drug approvals and patent expirations for several brand name drugs. It includes the brand and generic drug names, innovator company, potential generic partners, market size, and notes on patent challenges and expirations. Key drugs discussed include Pomalyst, KYPROLIS, Eliquis, Ozempic, Lynparza, and others. Potential generic filings and partners are listed, along with details on patent challenges and expected expiry dates ranging from 2025 to 2036.

    Copyright:

    © All Rights Reserved
    Download as XLSX, PDF, TXT or read online from Scribd
    Download as xlsx, pdf, or txt
    You are on page 1of 5

    Market

    Brand Name API Innovator Natco's partner Size (in


    $M)

    Pomalyst Pomalidomide Celgene Breckenridge 1400

    KYPROLIS carfilzomib Amgen Breckenridge 700

    Most likely a solo


    Bristol Myers
    Eliquis Apixaban filing (without any 10760
    Squibb + Pfizer
    partner)

    Amgen
    Kyprolis Carfilzomib (10mg) Breckenridge 800
    (OnyxPharma)
    Ozempic Semaglutide Pen (8mg/3ml) Novo Nordisk Mylan 5486
    AstraZeneca and
    Lynparza Olaparib Alembic 1226
    Merck
    Most likely a solo
    Lonsurf Trifluridine/Tipracil? Taiho filing (without any 222
    partner)

    Calquence Acalabrutinib AstraZeneca 1089

    Alvogen
    Imbruvica Ibrutinib (tablet) AbbVie (involved in co- 3426
    development as well)
    JANSSEN
    Yondelis Trabectedin 50
    PRODUCTS LP
    Tracleer Bosentan (32mg) J&J 20-30
    Zydelig Idelalisib 1200
    Para IV/FTE Settlement Y/N? Other Para IV Other FDA Approvals
    BRISTOL MYERS SQUIBB CO
    EUGIA PHARMA SPECIALITIES
    LTD
    Para IV Settlement US 9
    MYLAN PHARMACEUTICALS INC
    TEVA PHARMACEUTICALS USA
    INC
    DR REDDYS LABORATORIES LTD
    180 days exclusivity for APOTEX INC
    Settlement
    10 mg Natco/BRECKENRIDGE
    PHARMACEUTICAL

    Sigmapharm, Sunshine Lake and


    Unichem

    ACCORD HEALTHCARE INC


    AUROBINDO PHARMA LTD
    BIONPHARMA INC
    BRECKENRIDGE
    Mylan (now Viatris) and Micro PHARMACEUTICAL INC
    Para-IV
    Labs. BRISTOL MYERS SQUIBB CO
    PHARMACEUTICAL RESEARCH
    INSTITUTE
    INDOCO REMEDIES LTD
    MICRO LABS LTD
    MYLAN PHARMACEUTICALS INC
    ZYDUS PHARMACEUTICALS USA
    INC

    Para-IV and FTF

    Para-IV and FTF No one so far

    Para-IV and FTF Most likely No No one so far No one so far

    Para-IV (possible FTF) Most likely No No one so far

    Para-IV No one so far No one so far

    Para-IV and FTF N

    Para-IV Most likely No No one so far

    FTF
    Para-IV and FTF
    REMS Launch Possibility/Patent
    Drug Expiry

    Y 2025

    2027

    2027 or https://www.fiercepharma.com/special-report/top-15-blockbuster-patent-expirations-co
    https://news.bms.com/news/details/2021/The-Bristol-Myers-Squ
    2028

    2027

    last patent expiry in 2031

    2031

    last patent expiry in 2034, no


    info on settlment

    last patent expiry in 2036, no


    info on settlment

    last patent expiry in 2034, no https://12ft.io/proxy?q=https%3A%2F%2Fwww.thehindubusinessline.com%2Fcompanies


    info on settlment

    https://www.empr.com/home/news/zydelig-us-indications-withdrawn-for-follicular-lymp
    s/2021/The-Bristol-Myers-Squibb-Pfizer-Alliance-is-pleased-with-the-decision-by-the-U.S.-Court-of-Appeals-for-the-Federal-Circuit-uphold

    usinessline.com%2Fcompanies%2Fibrutinib-case-us-court-denies-natco-pharmas-partner-alvogens-appeal%2Farticle66143350.ece

    s-withdrawn-for-follicular-lymphoma-small-lymphocytic-leukemia/
    -for-the-Federal-Circuit-upholding-the-Eliquis-Patents/default.aspx

    2Farticle66143350.ece

    You might also like